Editorial: The Physiology and Pharmacology of Leucine-rich Repeat GPCRs by Brian J. Arey & James A. Dias
June 2016 | Volume 7 | Article 561
Editorial
published: 17 June 2016
doi: 10.3389/fendo.2016.00056
Frontiers in Endocrinology | www.frontiersin.org
Edited and Reviewed by: 
Pierre De Meyts, 
De Meyts R&D Consulting, Belgium
*Correspondence:
Brian J. Arey  
brian.arey@bms.com
Specialty section: 
This article was submitted to 
Molecular and Structural 
Endocrinology, 
a section of the journal 
Frontiers in Endocrinology
Received: 13 May 2016
Accepted: 23 May 2016
Published: 17 June 2016
Citation: 
Arey BJ and Dias JA (2016) Editorial: 
The Physiology and Pharmacology of 
Leucine-rich Repeat GPCRs. 
Front. Endocrinol. 7:56. 
doi: 10.3389/fendo.2016.00056
Editorial: the Physiology and 
Pharmacology of leucine-rich
repeat GPCrs
 
Brian J. Arey1* and James A. Dias2
1 Research and Development Bristol-Myers Squibb Co., Princeton, NJ, USA, 2 University at Albany, State University of New 
York, Albany, NY, USA
Keywords: G protein-coupled receptors, leucine-rich repeat family of receptors, lGr, GPCrs, physiology and 
pharmacology
The Editorial on the Research Topic
The Physiology and Pharmacology of Leucine-rich Repeat GPCRs
G protein-coupled receptors represent a large family of proteins that act as receptors for many types 
of physiological ligands, including peptides, metabolites, and lipids. These receptors are important 
for understanding physiology since they contribute to the regulation of all major organ systems. 
Additionally, they are also a key focus for the development of therapeutics for the treatment of patho-
physiology and are still recognized as the most druggable class of macromolecules today. GPCRs are 
classified into separate subfamilies (Classes A, B, and C) based on protein sequence homology in their 
transmembrane domains. Within the Class A family of GPCRs, these receptors can be further placed 
into sub-groups based on other structural features and similarities in function. In this Special Topic for 
Frontiers in Endocrinology: Molecular and Structural Endocrinology, we have focused on a subfamily 
of Class A GPCRs, the leucine-rich repeat family of receptors (LGR). The Physiology and Pharmacology 
of Leucine-rich Repeat GPCRs captures the continuum of structure to function, agonist to effector, and 
reproduction to metabolism that provides an overview of this important family of receptors.
The LGRs are characterized by the leucine-rich repeat structural motif (1) that provides the rigid 
structure of their large extracellular domains. The predicted heptahelical transmembrane domains 
and their sequence homology in this region with other receptors classify them as Class A GPCRs (2). 
Furthermore, there are currently three sub-groups of LGRs recognized. The Type A receptors have 
been extensively studied and are receptors for the pituitary and placental glycoprotein hormones. The 
endogenous ligands for the Type B (R-spondins) and C (relaxin) receptors have only recently been 
identified and rapid progress has been made that has advanced understanding of their structure and 
function. These receptors are important mediators in the regulation of diverse physiological process, 
such as reproduction, cardio-renal function, cell growth, and stem cell differentiation. Within this 
Special Topic, we seek to provide an understanding of this family of receptors while addressing both 
future opportunities and challenges that lay ahead.
Petrie et al. provide an overview of LGRs in terms of structure and organization that places this 
family of receptors within the larger context. This review provides in depth knowledge of the RXFP1 
and RXFP2 receptors whose cognate ligands are two insulin- related peptides, H2 relaxin, and 
INSL3. Thus, this review while calling out the uniqueness of the Type C LGRs RXFP1 and RXFP2, 
also introduces us nicely to the three Types of LGRs based on the size of their leucine-rich repeat 
extracellular domains.
Continuing on this theme of structure and function, activation of the most well studied of the 
LGRs, the gonadotropin receptors, is reviewed. The structural basis of activation of the gonadotropin 
receptors in the absence of a full crystal structure remains an enigma. However, we do know that the 
large extracellular domains are the binding site of the large heterodimeric ligands for these receptors. 
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A remaining question is the potential role of the other parts of 
the receptor structure in determining function. Banerjee and 
Mahale provide evidence using site-directed mutagenesis that 
signaling of the LH receptor is dependent on specific residues of 
the extracellular loops. Furthermore, Grzesik et al. demonstrate 
that differences in signaling by the two physiological ligands of 
the LH receptor, are at least in part, mediated by the hinge region 
of the extracellular domain. While both receptors coexist in the 
same cell during folliculogenesis, it is unclear how their agonist-
induced signals are parsed out. Further refining this thought, this 
paper addresses how one receptor can bind two nearly identical 
ligands and produce two different signaling profiles. It turns out 
that both hormone and extracellular loops coordinate to produce 
the breadth of nuance seen in signaling of these receptors. This 
seems a critical point if small molecules are to be developed which 
mimic some or all of these signaling patterns.
The physiological and therapeutic importance of the Type B 
and C receptors is discussed as well. The importance of RXFP1 in 
cancers is exemplified by Thanasupawat et al. in a review of new 
ligands for RXFP1 other than the canonical relaxin and INSL3; 
specifically C1q/TNF-related proteins and the role of RXFP1 as 
a brain cancer promoter. The theme is further explored with an 
in-depth look by Li et  al. of the Type B LGR4 where we learn 
that this receptor that is critical for developmental signaling and 
tissue homeostasis has as its ligand, R-spondins. We learn that 
R-spondins are the sole secreted potentiators of Wnt signaling 
and stem cell maintenance and appreciate that the Type B LGRs 
do not signal via G-proteins but do interact with the FZD–LRP 
complex to stimulate unique signaling pathways.
The LGR receptor family has been the subject of drug develop-
ment for decades. Focusing on improving the natural ligand for 
therapeutics based on these receptors, a perspective is provided 
by Szkudlinski on a journey toward the successful development 
of superagonists of the thyroid-stimulating hormone receptor, a 
Type A LGR. This review shines light on the potential of utilizing 
the naturally occurring ligands as a scaffold for engineering by 
structure-based drug design to develop “super biosimilars.” This 
is contrasted with the development of small molecule agonists 
and antagonists that act at this same class of LGR Type A as 
described by Nataraja et al. Here, we learn that it is possible to 
bypass the complicated interactions of heterodimeric ligands 
and the large extracellular domains of the LGR Type A receptors, 
to effect activation or inhibition with molecules a fraction of the 
size of the natural ligands. Although this represents a clear step 
forward in our ability to develop small molecule agonists and 
antagonists to these receptors, it is not without its challenges. 
In what would seem to be a reasonable assumption that cAMP 
as readout would predict efficacy in vivo, this is shown to not 
necessarily be the case. In the end, primary cells and iterative 
testing reveal the true candidate.
This concept is further exemplified in the article by Huang 
et al. An overwhelming majority of the preclinical animal test-
ing for relaxin treatment includes rodent models and, thus, the 
inability of small molecule agonists to activate the mouse receptor 
has hampered preclinical studies. In a search for animal models 
to study RXFP1 small molecule agonists as potential acute heart 
failure therapeutics, it was determined that non-human primate 
and porcine species could be used but the standard laboratory 
mouse model was unable to respond to the lead compound! These 
examples illustrate how development of small molecule therapeu-
tics is fraught with potential pitfalls and how appropriate models 
are needed for screening and selection of leads.
Finally, in an era of optogenetics and real-time inquiry, the 
use of transgenic methods may yield some recourse. Narayan 
describes how, for the gonadotropin receptors, a combination of 
knockout and knock-in approaches can yield novel mouse models 
that either simulates human disease or tests whether genomic vari-
ants can explain disease. In this regard, the luteinizing hormone 
receptor has been very well studied using transgenic animals to 
better understand the effect of mutations causing constitutive 
activation as a model for Familial Male Precocious Puberty.
Advanced methods in cellular imaging are also available 
which will aid in the study of LGR signaling. Certainly in the area 
of the gonadotropin receptors, these methods have contributed to 
an understanding that, although the canonical cAMP pathway is 
operative in the gonadotropin receptors, additional pathways are 
likely at play. Thus, Ayoub et al. describes the use of biolumines-
cence resonance energy transfer (BRET) to study activation of 
gonadotropin receptors in living cells. Using this method, they 
confirm that these receptors exhibit biased agonism.
It has been nearly a century since Smith discovered the relation-
ship between pituitary extracts and follicular development and 
60 years since Hisaw discovered relaxin as a hormone that could 
cause a loosening of the pubic symphysis prior to parturition. These 
seminal findings have led to the identification of the importance 
of these peptides on the physiology of the reproductive system 
but have also ultimately revealed a more complex endocrine role 
of these hormones and the identification of a unique family of 
receptors. Research over the ensuing decades has revealed that the 
LGRs exert varied and comprehensive controls on processes that 
include but are certainly not limited to reproduction and point to 
their potential as therapeutic targets to treat disease.
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